

REMARKS

Prior to the present Office Action, claims 1-29, 38 and 66-81 were pending in this application, with claims 80 and 81 being withdrawn as reading on a non-elected invention. There were thus a total of 46 claims, 3 of which were independent.

5 Applicants have canceled claims 1-29, 38 and 81 and added claims 82-112. Claims 66-80 and 82-112 remain pending, which is a total of 46 claims, 3 of which are independent.

Independent claim 66 is allowed. Consequently, Applicants have canceled all non-allowed independent claims and their dependents (including claim 81). Please note the dependency change in claim 73, and an antecedent fix in claim 75.

10 New claims 82-84 depend from allowable claims 66.

New independent claims 85 and 100 include all of the limitations from allowed claim 66, with small additions, and therefore should also be allowed. This was discussed during a telephone conference between the undersigned and Examiner Fisher on November 18, 2010. Dependent claims 86-99 and 101-112 have previously been of record and do not raise new
15 issues. No new matter is added by the present claim additions.

Based on the foregoing remarks and amendments Applicants believe claims 66-80 and 82-112 are in condition for allowance and such action is solicited.

20 Respectfully submitted,

Date: November 19, 2010

/Guy Cumberbatch, Reg. No. 36,114/
Guy Cumberbatch, Reg. No. 36,114
(805) 201-3006
c/o Stephen Donovan
Registration number 33,433

30 Please send all inquiries and correspondence to:

Patent Department
Allergan, Inc. T2-7H
2525 Dupont Drive
Irvine, California 92612
35 Telephone: 714 246 4026
Fax: 714 246 4249